[Cervico-facial lymphangiomas. What's the appropriate management?].
BACKGROUND
Cystic hygroma is a benign and uncommon vascular tumor. Therapeutic difficulties are variables and are discussed with regard to different clinical forms. The curative treatment is surgical.


OBJECTIVE
The purpose of this study is to discuss the management of the vascular malformation.


METHODS
We present a retrospective study over a period of 11 years (1995- 2005); about 12 patients treated and followed in ENT department of Habib Thameur Hospital of Tunis.


RESULTS
The average age of the patients was 29 years and the average size of the tumor was 7 cm in diameter. A voluminous cervical mass was noted in 3 cases. Local inflammation with respiratory restriction were observed in one patient. Surgical treatment was performed in 8 cases without recurrences. Injection of sclerosing agent (Ethibloc) was indicated in 4 cases because of the volume of the tumor. The following was marked by reduction of the tumor volume. Surgical excision was completed in one case.


CONCLUSIONS
The management of lymphangioma is challenging. Surgical excision is the best treatment in limited forms. The prognosis of voluminous lymphangiomas is transformed by sclerosing injections.
Ben Gamra
Olfa
O
Service ORL & Chirurgie Cervico-Faciale, Hôpital Habib Thameur Tunis, Tunisie.
Mbarek
Chiraz
C
Neji
R
R
Chammakhi
Ch
Ch
Daoued
R
R
Hariga
Ines
I
Zribi
Sarra
S
El Khedim
Abdelkader
A
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003973:Diatrizoate / Q000008:administration & dosage*; D004338:Drug Combinations; D005227:Fatty Acids / Q000008:administration & dosage*; D005260:Female; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007223:Infant; D015552:Injections, Intralesional; D018191:Lymphangioma, Cystic / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011409:Propylene Glycols / Q000008:administration & dosage*; D012189:Retrospective Studies; D012597:Sclerosing Solutions / Q000008:administration & dosage*; D016896:Treatment Outcome; D015028:Zein / Q000008:administration & dosage*
D004338:Drug Combinations; D005227:Fatty Acids; D011409:Propylene Glycols; D012597:Sclerosing Solutions; D003973:Diatrizoate; D015028:Zein; C020481:alcoholic prolamine solution